https://www.selleckchem.com/pr....oducts/pf-562271.htm
Validation of the EORTC nomogram showed a C-statistic of 0·70 (95 per cent c.i. 0·68 to 0·71) for recurrence-free survival, with excellent calibration (R =0·99; P=0·999, Hosmer-Lemeshow test). This population-based validation confirmed the value of the EORTC nomogram in predicting recurrence-free survival in patients with SN-negative melanoma. The EORTC nomogram could be used in clinical practice for personalizing follow-up and selecting high-risk patients for trials of adjuvant systemic therapy. This population-based validation confi
Like
Comment
Share
